secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2025-06-27T23:59:59+00:00
Accession:  0000950170-25-090616
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx receives FDA Breakthrough Therapy Designation for GTX-102 in Angelman syndrome
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation for GTX-102 (apazunersen) for Angelman syndrome.
- Based on Phase 1/2 study in 74 patients (4-17 years) with full maternal UBE3A deletion showing consistent developmental gains.
- Designation aims to expedite development and review; may enable rolling submission and enhanced FDA guidance.
- Positive data shows rapid, sustained improvements across multiple symptom domains over up to three years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025090616/0000950170-25-090616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025090616/rare-20250627.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-090616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer